Profil
Mei Hui Li is currently the Vice Chairman & Chief Executive Officer at Cinemark Co. Ltd. She also holds positions as an Independent Director at CTCI Advanced Systems Inc., FOCI Fiber Optic Communications, Inc., and Director at Advagene Biopharma Co., Ltd. Ms. Li previously worked as the Managing Director at Taiwan Secom Co., Ltd. She graduated from National Taiwan University.
Aktive Positionen von Mei Hui Li
| Unternehmen | Position | Beginn |
|---|---|---|
| CTCI ADVANCED SYSTEMS INC. | Direktor/Vorstandsmitglied | 26.06.2014 |
| FOCI FIBER OPTIC COMMUNICATIONS, INC. | Direktor/Vorstandsmitglied | 06.06.2018 |
| ADVAGENE BIOPHARMA CO., LTD. | Direktor/Vorstandsmitglied | - |
Cinemark Co. Ltd. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Mei Hui Li
| Unternehmen | Position | Ende |
|---|---|---|
| TAIWAN SECOM CO., LTD. | Corporate Officer/Principal | - |
Ausbildung von Mei Hui Li
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Taiwan Secom Co., Ltd.
Taiwan Secom Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Provides system security services | Commercial Services |
CTCI Advanced Systems Inc.
CTCI Advanced Systems Inc. Electrical ProductsProducer Manufacturing Manufactures control system software and hardware | Producer Manufacturing |
National Taiwan University
National Taiwan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FOCI Fiber Optic Communications, Inc.
FOCI Fiber Optic Communications, Inc. Electrical ProductsProducer Manufacturing Manufactures and sells fiber optic interconnectors | Producer Manufacturing |
Cinemark Co. Ltd. | |
Advagene Biopharma Co., Ltd.
Advagene Biopharma Co., Ltd. BiotechnologyHealth Technology Engages in the development of products such as nasal influenza vaccine, airway allergy immunotherapy and COVID-19 immunotherapy | Health Technology |
















